A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs AAB 003 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.